Direct-to-Consumer Genetic Testing Market worth 6.15 billion by 2030, growing at a CAGR of 17.19 percent - Exclusive - openPR
| HBP Stock | CAD 0.95 0.08 9.20% |
About 55% of Helix BioPharma's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Helix BioPharma Corp suggests that some traders are interested. Helix BioPharma's investing sentiment overview a quick insight into current market opportunities from investing in Helix BioPharma Corp. Many technical investors use Helix BioPharma Corp stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Helix |
Direct-to-Consumer Genetic Testing Market worth 6.15 billion by 2030, growing at a CAGR of 17.19 percent - Exclusive openPR
Read at news.google.com
 |
Helix BioPharma Fundamental Analysis
We analyze Helix BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Helix BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Helix BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Helix BioPharma is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Helix BioPharma Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Helix BioPharma stock to make a market-neutral strategy. Peer analysis of Helix BioPharma could also be used in its relative valuation, which is a method of valuing Helix BioPharma by comparing valuation metrics with similar companies.
Peers
Helix BioPharma Related Equities
| TH | Theratechnologies | 7.06 | ||||
| EDT | Spectral Med | 1.79 | ||||
| MBX | Microbix Biosystems | 3.23 | ||||
| ONC | Oncolytics Biotech | 3.79 |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.